Is Halozyme Therapeutics, Inc. HALO stock halal to invest in?

Yes, as of August 2026, Halozyme Therapeutics, Inc. stock (HALO) is classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening halal stocks. Halozyme Therapeutics, Inc. currently passes all four AAOIFI financial screens: non-permissible income remains below 5% of total revenue, interest-bearing investments and interest-bearing debt each remain below 30% of market capitalisation, and the company has no impermissible preference share structure. The stock's current purification factor is 99.65%. Compliance is reassessed every month as updated screening data arrives, and a stock's status can change when new financial reports are released. You can always check the current status of Halozyme Therapeutics, Inc. and explore other Shariah compliant stocks in the Tabadulat app.

How often is Halozyme Therapeutics, Inc. HALO reviewed for Shariah compliance?

Tabadulat reviews Halozyme Therapeutics, Inc. HALO for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Halozyme Therapeutics, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Halozyme Therapeutics, Inc. HALO pass the AAOIFI Non Permissible Income criteria?

Yes, as of August 2026, Halozyme Therapeutics, Inc. stock (HALO) passes the AAOIFI non-permissible income screen. Under AAOIFI Shariah Standard No. 21, income from impermissible sources (such as interest or riba, conventional financial services, alcohol, gambling, or tobacco) must remain below 5% of a company's total revenue. Halozyme Therapeutics, Inc.'s income from non-permissible sources is currently within this 5% threshold. Even permissible levels of incidental impure income should still be purified: investors donate the corresponding share of dividends to charity, as reflected in the stock's purification factor. This screen is reassessed monthly using the company's latest financial disclosures.

Does Halozyme Therapeutics, Inc. HALO pass the AAOIFI Interest Bearing Investments criteria?

Yes, as of August 2026, Halozyme Therapeutics, Inc. stock (HALO) passes the AAOIFI interest-bearing investments screen. Under AAOIFI Shariah Standard No. 21, the cash a company places in interest-earning instruments (such as conventional deposits, bonds, treasury bills and money-market funds) must remain below 30% of its market capitalisation. This limit ensures shareholders are not materially profiting from riba (interest). Halozyme Therapeutics, Inc.'s interest-bearing investments are currently within the 30% threshold. Because the ratio is measured against market capitalisation, it can move with the share price as well as the balance sheet, which is why Tabadulat rescreens the stock every month.

Does Halozyme Therapeutics, Inc. HALO pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of August 2026, Halozyme Therapeutics, Inc. stock (HALO) passes the AAOIFI interest-bearing debt screen. Under AAOIFI Shariah Standard No. 21, a company's borrowings that accrue interest (conventional bank loans, bonds and similar riba-based financing) must remain below 30% of its market capitalisation. This cap limits shareholders' exposure to interest-based leverage. Halozyme Therapeutics, Inc.'s interest-bearing debt is currently within the 30% threshold. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Halozyme Therapeutics, Inc. HALO stock?

As of August 2026, the dividend purification factor for Halozyme Therapeutics, Inc. (HALO) is 99.65%. Purification (tazkiyah) is the practice of donating to charity the portion of dividend income attributable to incidental non-permissible sources, typically interest earned on a company's cash, and AAOIFI methodology requires it even for fully compliant stocks. The purification factor is the figure halal investors use to work out that donation on Halozyme Therapeutics, Inc. dividends. It is recalculated with each monthly screening as new financial data arrives, and the Tabadulat app can help you calculate and track purification across your whole portfolio.

Does Halozyme Therapeutics, Inc. HALO pass the AAOIFI Preference Share screen?

Yes, as of August 2026, Halozyme Therapeutics, Inc. stock (HALO) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Halozyme Therapeutics, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Halozyme Therapeutics, Inc.

NASDAQ

Shariah-Compliant

Not Shariah

HALO

About

Halozyme Therapeutics, Inc.

HALO

Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

350

Website:

https://halozyme.com

HALO

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.

Halozyme Therapeutics, Inc.

About

Halozyme Therapeutics, Inc.

HALO

Frequently asked questions

Is Halozyme Therapeutics, Inc. HALO stock halal to invest in?

How often is Halozyme Therapeutics, Inc. HALO reviewed for Shariah compliance?

Does Halozyme Therapeutics, Inc. HALO pass the AAOIFI Non Permissible Income criteria?

Does Halozyme Therapeutics, Inc. HALO pass the AAOIFI Interest Bearing Investments criteria?

Does Halozyme Therapeutics, Inc. HALO pass the AAOIFI Interest Bearing Debt criteria?

What is the dividend purification factor for Halozyme Therapeutics, Inc. HALO stock?

Does Halozyme Therapeutics, Inc. HALO pass the AAOIFI Preference Share screen?

How do I buy Halozyme Therapeutics (HALO) stock?

Open your account.

Deposit.

Screen.